Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma

Cancer

Volumn 115, Issue 12, 2009, Pages 2630-2639

  Reni, Michele ^a   Cereda, Stefano ^a   Balzano, Gianpaolo ^a   Passoni, Paolo ^a   Rognone, Alessia ^a   Fugazza, Clara ^a   Mazza, Elena ^a   Zerbi, Alessandro ^a   Di Carlo, Valerio ^a   Villa, Eugenio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Carbohydrate antigen 19 9; Chemotherapy; Pancreatic cancer; Prognostic factors

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; CA-19-9 ANTIGEN; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 67649220204     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24302     Document Type: Article

References (30)

1. McPhee SJ. Disorders of the exocrine pancreas. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002:157-164.
2. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd.. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275. (Pubitemid 34831525)
3. Rocha Lima CMS, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-3783. (Pubitemid 41095218)
4. Heinemann V, Quietzch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic carcinoma. J Clin Oncol. 2006;24:3946-3952. (Pubitemid 46630743)
5. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516. (Pubitemid 46243495)
6. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-2217. (Pubitemid 46954645)
7. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. (Pubitemid 46972777)
8. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer [abstract]. Eur J Cancer. 2005;3:12. Abstract PS11.
9. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol. 2005;6:369-376.
10. Reni M, Bonetto E, Cordio S, et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology. 2006;6:454-463. (Pubitemid 44624279)
11. Brambs HJ, Claussen CD. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy. 1993;25:58-68.
12. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013-1016. (Pubitemid 30128852)
13. Ishii H, Okada S, Sato T, et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology. 1997;44:279-283. (Pubitemid 27096053)
14. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195-199. (Pubitemid 41133205)
15. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-743. (Pubitemid 41486431)
16. Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie. 2003;26:462-467.
17. Ziske C, Schlie C, Gorschluter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413-1417. (Pubitemid 37386593)
18. Boeck S, Stieber P, Holdenrieder S, Weckbach S, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2007;70:255-264.
19. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour marker response to chemotherapy in patients with advanced pancreatic cancer treated in a randomized controlled trial. Lancet Oncol. 2008;9:132-138.
20. Reni M, Passoni P, Panucci MG, et al. Definitive results of a phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma. J Clin Oncol. 2001;19:2679-2686. (Pubitemid 32441373)
21. Reni M, Cereda S, Bonetto E, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest. 2007;25:594-598. (Pubitemid 350135737)
22. Reni M, Cereda S, Bonetto E, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2007;59:361-367. (Pubitemid 46025523)
23. Reni M, Cereda S, Passoni P, et al. A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma [abstract]. Proc Am Soc Clin Oncol. 2007;25. Abstract 4628.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214. (Pubitemid 11167383)
25. Therasse P, Arbuck SG, Eisenhaur EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2004;92:205-216.
26. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710-719. (Pubitemid 14202071)
27. Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Stat Med. 1996;15:2797-2812. (Pubitemid 27011058)
28. Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32:35-41. (Pubitemid 36323101)
29. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001;92:569-577. (Pubitemid 32735192)
30. Heinemann V, Schermoly MM, Stieber P, et al. CA19-9: a predictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res. 1999;19:2433-2436. (Pubitemid 29392389)